# enGene Therapeutics Inc.: overview ENGN · Nasdaq · CIK 1980845 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Oct 31 Pages: [Overview](/companies/engn.md) · [Financials](/companies/engn/financials.md) · [Filings](/companies/engn/filings.md) · [Insiders](/companies/engn/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [0.48](/filings/0001193125-26-097541.md) | [(0.51)](/filings/0001193125-26-270386.md) | [(0.57)](/filings/0001193125-26-384383.md) | not reported | [0.44](/filings/0001193125-26-097541.md) | [(0.43)](/filings/0001193125-26-270386.md) | [(0.47)](/filings/0001193125-26-384383.md) | | Free cash flow | $m | [(19.8) d](/filings/0001193125-25-328743.md) | [(26.0)](/filings/0001193125-26-097541.md) | [(23.0) d](/filings/0001193125-26-270386.md) | [(26.3) d](/filings/0001193125-26-384383.md) | [(25.4) d](/filings/0001193125-25-328743.md) | [(29.1)](/filings/0001193125-26-097541.md) | [(30.6) d](/filings/0001193125-26-270386.md) | [(18.9) d](/filings/0001193125-26-384383.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY (2022-10-31) | FY2023 (2023-10-31) | FY2024 (2024-10-31) | FY2025 (2025-10-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [44.30](/filings/0000950170-24-008125.md) | [151.22](/filings/0000950170-24-138472.md) | [1.46](/filings/0001193125-25-328743.md) | [2.29](/filings/0001193125-25-328743.md) | | Free cash flow | $m | [(17.7)](/filings/0000950170-24-008125.md) | [(25.1)](/filings/0000950170-24-138472.md) | [(49.2)](/filings/0001193125-25-328743.md) | [(101)](/filings/0001193125-25-328743.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/engn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BML Capital Management, LLC](/funds/1616824.md) | 2026-06-30 | $11.5m | 6,669,908 | | New +6,669,908 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $10.8m | 6,256,662 | | New +6,256,662 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $8.3m | 4,822,169 | | New +4,822,169 | | [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $4.6m | 2,675,876 | | New +2,675,876 | | [Nextech Invest Ltd.](/funds/1595430.md) | 2026-06-30 | $4.0m | 2,324,943 | | New +2,324,943 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $3.6m | 2,104,986 | | New +2,104,986 | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $2.9m | 1,667,430 | | New +1,667,430 | | [ACORN CAPITAL ADVISORS, LLC](/funds/2054410.md) | 2026-06-30 | $2.2m | 1,271,257 | | New +1,271,257 | | [Peapod Lane Capital LLC](/funds/2050979.md) | 2026-06-30 | $1.9m | 1,102,149 | | New +1,102,149 | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $1.7m | 1,007,344 | | New +1,007,344 | ## Recent filings [All 267 filings](/companies/engn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-08 | 07:36 ET | [10-Q](/filings/0001193125-26-384383.md) | Quarterly report, period 2026-07-31 | 0001193125-26-384383 | | 2026-09-08 | 07:33 ET | [8-K](/filings/0001193125-26-384380.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-384380 | | 2026-08-11 | 16:03 ET | [8-K](/filings/0001193125-26-344559.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-344559 | | 2026-07-17 | 16:05 ET | [8-K](/filings/0001193125-26-307795.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-307795 | | 2026-07-16 | 08:06 ET | [8-K](/filings/0001193125-26-305418.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-305418 | | 2026-06-18 | 16:06 ET | [8-K/A](/filings/0001193125-26-275815.md) | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors | 0001193125-26-275815 | | 2026-06-15 | 09:16 ET | [10-Q](/filings/0001193125-26-270386.md) | Quarterly report, period 2026-04-30 | 0001193125-26-270386 | | 2026-06-15 | 09:14 ET | [8-K](/filings/0001193125-26-270384.md) | 2.02 Results of operations; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-270384 | | 2026-06-10 | 16:09 ET | [8-K](/filings/0001193125-26-265830.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-265830 | | 2026-05-08 | 16:06 ET | [DEF 14A](/filings/0001140361-26-020024.md) | Proxy statement, period 2026-06-09 | 0001140361-26-020024 | ## Latest annual report [Form 10-K for the fiscal year ended Oct 31, 2025](/filings/0001193125-25-328743.md), filed Dec 22, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1980845 - Tickers: ENGN, ENGNW - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: Z4 - Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.